Novartis experimental prostate cancer drug gets FDA breakthrough designation
Novartis announced on Wednesday that the FDA granted Breakthrough Therapy designation to an experimental therapy that targets advanced castration-resistant prostate cancer. The agency said the decision was based on positive data from a Phase 3 clinical trial evaluating LuPSMA-617. Breakthrough Therapy designation is granted to medicines being evaluated for serious conditions where early clinical evidence…